Within the subgroup of non-Her2-enriched breast cancers, patients with either HER2-positive or TOP2A-abnormal disease were limited in numbers and did not show a differential treatment effect as compared to patients with HER2 normal and TOP2A normal disease (data not shown). This evidence concerns the gene ERBB2 and breast cancer.